HAA Regimen As Induction Chemotherapy For Newly Diagnosed Acute Myelogenous Leukemia

Objective To analyse the treatment outcome of 150 newly diagnosed adult acute myeloid leukemia(AML)patients,and explore the efficacy and safety of HAA regimen,which consisting of homoharringtonine(HHT),cytarabine(Ara-C)and aclarubicin(Acla).Method All of the patients entered the clinical trial were treated with HAA regimen.The complete remission(CR)rate was observed.Cox-survival ananlysis methed was used to estimate survival rates and differences were compared with 2-sided log-rank test.Result Out of the 150 patients,121(81%)attained CR and the first single course of this induction regimen resulted in a CR rate of 68%.The CR rate of 97%,84%and 38%were achieved in patients with favorable,intermediate and unfavorable cytogenetics,respectively.For the patients with CR,the median follow-up was 16.5(1.5～100.5)months,and the estimated 3-year survival rate was 45%.The estimated 3-year relapse free survival(RFS)was 52%for the 121 patients with CR.Conclusion HAA regimen is a safe regimen and it is efficacious, well-tolerable induction therapy for newly diagnosed AML.A high CR rate can be achieved with only one or two course of this regimen.